P3354
P3781
Osimertinib and Navitoclax in Treating Patients With EGFR-Positive Previously Treated Advanced or Metastatic Non-small Cell Lung CancerOral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerStudy of Osimertinib + SRS vs SRS Alone for Brain Metastases in EGFR Positive PatientsA Multi-Centre, Prospective, Non-Interventional Study to Intensively Monitor the Safety of Osimertinib in Clinical Practice Among Chinese NSCLC PatientsCombination of Osimertinib and Aspirin to Treat 1st Generation Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor(EGFR-TKI)Resistance Non-small Cell Lung Cancer ( NSCLC)Osimertinib With Stereotactic Radiosurgery (SRS) in Brain Metastases From EGFR Positive NSCLCCombination of Osimertinib and Aspirin to Treat Osimertinib Resistance Non-small Cell Lung Cancer ( NSCLC)A Study of the Combination of Osimertinib, Platinum and Etoposide for Patients With Metastatic EGFR Mutant Lung CancersA Randomised Phase II Trial of Osimertinib With or Without SRS for EGFR Mutated NSCLC With Brain MetastasesAssessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung CancerUncommon EGFR AZD9291TAGRISSO (Osimertinib) in NSCLC Patients in Whom T790 Mutations Are Detected by Liquid Biopsy Using BALF, Plasma or Pleural EffusionA Phase 2 Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naïve Advanced EGFR Mutant Lung CancerOsimertinib for NSCLC With EGFR Exon 20 Insertion MutationSapanisertib and Osimertinib in Treating Patients With Stage IV EGFR Mutation Positive Non-small Cell Lung Cancer After Progression on a Previous EGFR Tyrosine Kinase InhibitorOsimertinib In EGFR Mutant Lung CancerOpen-label PET Study With [11C]Osimertinib in Patients With EGFRm NSCLC and Brain MetastasesDS-1205c With Osimertinib for Metastatic or Unresectable Epidermal Growth Factor Receptor (EGFR)-Mutant Non-Small Cell Lung CancerStudy to Determine the Effect of Food on the Blood Levels of AZD9291 Following Oral Dosing of a Tablet Formulation in Patients With Non-Small Cell Lung CancerStudy to Assess the Effect of Itraconazole (a CYP3A4 Inhibitor) on the Pharmacokinetics of AZD9291, in Patients With EGFR Positive Non-small Cell Lung Cancer. Patients Will be Chosen From Those Who Have Already Been Prescribed an EGFR TKI MediciA Study of Dacomitinib in Patients With Metastatic EGFR Mutant Lung Cancer Previously Treated With OsimertinibEfficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.Phase I, Study in Chinese NSCLC PatientsNiraparib in Combination With Osimertinib in EGFR-Mutated Advanced Lung CancerStudy of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung CancerFirst-line Treatment With Osimertinib in EGFR-mutated Non-small Cell Lung Cancer, Coupled to Extensive Translational StudiesStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)Study to Assess the Effect of Rifampicin on Blood Levels and Safety of AZD9291, in Patients With EGFRm+ NSCLCStudy to Assess the Effect of AZD9291 on the Blood Levels of Simvastatin in Patients With EGFRm+ NSCLCT-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLCOsimertinib Plus Savolitinib in EGFRm+/MET+ NSCLC Following Prior OsimertinibOsimertinib in Subjects With Advanced Non-Small Cell Lung Cancer EGFR-T790M Mutation-positive18F-FDG PET and Osimertinib in Evaluating Glucose Utilization in Patients With EGFR Activated Recurrent GlioblastomaA Study Osimertinib in Patients With Stage 4 Non-small Cell Lung Cancer With Uncommon EGFR MutationsAn Open-Label Phase 1/2 Study of Itacitinib in Combination With Osimertinib in Subjects With Non-Small Cell Lung CancerOleclumab (MEDI9447) EGFRm NSCLC Novel Combination StudyMEchanisms of Resistance in EGFR Mutated Nonpretreated Advanced Lung Cancer Receiving OSimErtibOsimertinib in Treating Participants With Stage I-IIIA EGFR-mutant Non-small Cell Lung Cancer Before SurgeryGlutaminase Inhibitor CB-839 Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer
P4844
In vitro modeling to determine mutation specificity of EGFR tyrosine kinase inhibitors against clinically relevant EGFR mutants in non-small-cell lung cancerOsimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib.Osimertinib: First Global Approval.AZD9291 in EGFR-mutant advanced non-small-cell lung cancer patients.Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.Third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.Osimertinib in untreated epidermal growth factor receptor (EGFR)-mutated advanced non-small cell lung cancer.Cost-effectiveness of Osimertinib in the First-Line Treatment of Patients With EGFR-Mutated Advanced Non-Small Cell Lung Cancer.Afatinib in the first-line treatment of patients with non-small cell lung cancer: clinical evidence and experienceAcquisition of T790M resistance mutation in a patient with advanced adenocarcinoma harbouring uncommon mutations: a case report and literature reviewCombined plasma and tissue genotyping of EGFR T790M benefits NSCLC patients: a real-world clinical exampleHeterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in this Complex Clinical ScenarioPneumatosis intestinalis induced by osimertinib in a patient with lung adenocarcinoma harbouring epidermal growth factor receptor gene mutation with simultaneously detected exon 19 deletion and T790 M point mutation: a case reportClinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M MutationNewer-Generation EGFR Inhibitors in Lung Cancer: How Are They Best Used?Rapid effect of osimertinib re-challenge on brain metastases developing during salvage cytotoxic chemotherapy after osimertinib treatment failure: A case reportDifferent incidence of interstitial lung disease according to different kinds of EGFR-tyrosine kinase inhibitors administered immediately before and/or after anti-PD-1 antibodies in lung cancerTransformation of epidermal growth factor receptor T790M mutation-positive adenosquamous carcinoma of the lung to small cell carcinoma and large-cell neuroendocrine carcinoma following osimertinib therapy: an autopsy case reportFirst-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysisMolecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare mutationsThird generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLCMixed response to osimertinib and the beneficial effects of additional local therapyOsimertinib for EGFR-Mutant Lung Cancer with Brain Metastases: Results from a Single-Center Retrospective StudySuccessful Response to Osimertinib Rechallenge after Intervening Chemotherapy in an EGFR T790M-Positive Lung Cancer PatientCNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung CancerA Phase II Trial of Osimertinib in the Second-Line Treatment of Non-small Cell Lung Cancer with the EGFR T790M Mutation, Detected from Circulating Tumor DNA: LiquidLung-O-Cohort 2Efficacy and Safety Data of Osimertinib in Elderly Patients with NSCLC Who Harbor the EGFR T790M Mutation After Failure of Initial EGFR-TKI TreatmentOsimertinib Treats CNS Metastases in NSCLC
P921
description
chemesch Verbindung
@lb
chemical compound
@en-ca
chemical compound
@en-gb
chemical compound, a third-gen ...... nomas with a specific mutation
@en
chemická sloučenina
@cs
chemická zlúčenina
@sk
chemiese verbinding
@af
chemische Verbindung
@de
chemische Verbindung
@de-ch
chemische stof
@nl
name
Osimertinib
@de
Osimertinib
@fr
Osimertinib
@vi
osimertinib
@cs
osimertinib
@en
osimertinib
@it
أوزيميرتينيب
@ar
اوسیمرتینیب
@fa
オシメルチニブ
@ja
奥希替尼
@zh
type
label
Osimertinib
@de
Osimertinib
@fr
Osimertinib
@vi
osimertinib
@cs
osimertinib
@en
osimertinib
@it
أوزيميرتينيب
@ar
اوسیمرتینیب
@fa
オシメルチニブ
@ja
奥希替尼
@zh
altLabel
AZD 9291
@en
AZD-9291
@en
AZD9291
@en
Mereletinib
@en
N-(2-{[2-(dimethylamino)ethyl] ...... yl]amino}phenyl)prop-2-enamide
@en
Osimertinib
@en
Tagrisso®
@en
mereletinib (obsolete INN)
@en
오시메르티닙
@ko
타그리소
@ko
prefLabel
Osimertinib
@de
Osimertinib
@fr
Osimertinib
@vi
osimertinib
@cs
osimertinib
@en
osimertinib
@it
أوزيميرتينيب
@ar
اوسیمرتینیب
@fa
オシメルチニブ
@ja
奥希替尼
@zh
P486
P592
P6366
P638
P661
P662
P665
P683
P1579
P2067
P2115
N0000192141
P231
1421373-65-0
P233
CN1C=C(C2=CC=CC=C21)C3=NC(=NC=C3)NC4=C(C=C(C(=C4)NC(=O)C=C)N(C)CCN(C)C)OC
P234
1S/C28H33N7O2/c1-7-27(36)30-22 ...... H2,2-6H3,(H,30,36)(H,29,31,32)